No volume to the upside, but very nice volume to the down side. Not good for u bag holders.
Amag doing what it does best "TANKING". LOL... Buying the dips must be extremely pain full for all u bag holders. Hedge funds slowly but surly unloading their positions. Should tank under $20. Can we say margin call coming for most bag holders?
What a dog for a stock. If you are long, its time to cut your loses. Is this dog heading to $20?
Have you no shame in pumping that garbage stock AMAG on KBIO message board? My God how much have you lost being long that p.o.s? I know you bought AMAG in the mid fifties, now it's trading under $26.Yell baby your quite the investor.
Please, only thing shorts have to worry about, is whether or not AMAG will make another 52 week low.
the U.S. Food and Drug Administration rejected a single dose use of its hormone injection, Makena, the agency's second rejection in six months. Never going to happen. Keep pumping, while the big boys keep dumping. $77 high to a new 52 week low of $26.40 & still dropping.
500 million share repurcahse program just announce
Told u it would trade under $20 this week. Dang I'm good at this... So how is that investment at $55 working out for you? LOL...
The company had referred to a cash crunch so severe that it didn't have the resources to file its 10-Q for Q3
And you fools are buying this #$%$ at $20. Dang I hope to God i can find some shares tomorrow to short the crab out of pos
So for 2016 Earning might $3 at best, not the $6
$20 stock at best!
Makena, the agency's second rejection in six months. Not Good tanks to $20 or less
AMAG Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration rejected a single dose use of its hormone injection, Makena, the agency's second rejection in six months.
Makena is currently approved and marketed in a multi-dose injection and remains unaffected by FDA's rejection of the single-dose vial.
The multiple dose is approved to be used to lower premature birth in pregnant women who has had one premature baby.
Makena, the only FDA-approved treatment indicated to reduce the risk of preterm birth in women who are pregnant with one baby and who have spontaneously delivered one preterm baby in the past, is currently marketed in a multi-dose vial, containing five weekly injections. The multi-dose Makena vial remains available for prescribing and is not affected by the letter from FDA regarding the single-dose application.
AMAG Pharmaceuticals, Inc. today received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for its application seeking approval for a single-dose vial of Makena (hydroxyprogesterone caproate injection) to reduce the risk of preterm birth in certain at-risk patients. A CRL is a communication from the FDA that informs companies that an application cannot be approved in its present form. In the letter, the FDA requested additional information and the company is working with its manufacturer to submit a response with the requested information to the FDA as quickly as possible.